Afficher la notice abrégée

Time to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus

dc.rights.licenseopenen_US
dc.contributor.authorCHALOUNI, Mathieu
dc.contributor.authorVAN SANTEN, Daniela K
dc.contributor.authorBERENGUER, Juan
dc.contributor.authorJARRIN, Inmaculada
dc.contributor.authorMIRO, Jose M
dc.contributor.authorKLEIN, Marina B
dc.contributor.authorYOUNG, Jim
dc.contributor.authorTORGERSEN, Jessie
dc.contributor.authorRENTSCH, Christopher T
dc.contributor.authorGILL, M John
dc.contributor.authorEPSTEIN, Rachel L
dc.contributor.authorLINAS, Benjamin
dc.contributor.authorZANGERLE, Robert
dc.contributor.authorSURIAL, Bernard
dc.contributor.authorRAUCH, Andri
dc.contributor.authorTOULOUMI, Giota
dc.contributor.authorPAPADOPOULOS, Antonios
hal.structure.identifierStatistics In System biology and Translational Medicine [SISTM]
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorWITTKOP, Linda
dc.contributor.authorVAN DER VALK, Marc
dc.contributor.authorBOYD, Anders
dc.contributor.authorMONFORTE, Antonella D'Arminio
dc.contributor.authorPUOTI, Massimo
dc.contributor.authorLOGAN, Roger W
dc.contributor.authorREIN, Sophia M
dc.contributor.authorHERNAN, Miguel A
dc.contributor.authorLODI, Sara
dc.date.accessioned2025-04-10T15:39:12Z
dc.date.available2025-04-10T15:39:12Z
dc.date.issued2025-02-19
dc.identifier.issn1473-5571en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/206104
dc.description.abstractEnOBJECTIVE: People with HIV-HCV co-infection need antiretroviral treatment (ART) to suppress HIV and direct-acting antivirals (DAAs) to cure HCV. ART is typically prioritized, but delays in DAA initiation may increase the risk of liver-related events and HCV transmission to others. DESIGN: Target trial emulation with observational data collected in routine clinical practice from a collaboration of cohorts from Europe and North America. METHODS: We included DAA-naïve adults with HIV-HCV co-infection who achieved HIV virologic suppression (HIV RNA<50 copies/mL) after starting ART between 2013-2020. We 1) estimated the probability of not initiating DAAs at 6 and 36 months after HIV virologic suppression, and 2) emulated a target trial of early (≤6 months after HIV virological suppression) versus delayed (>6 months) DAA initiation and the 36-month risk of liver-related events (liver decompensation or hepatocellular carcinoma). RESULTS: Of 862 eligible individuals (median age 46 years; interquartile range 36 to 56), 14% were women, and 52% had a history of injection drug use. The 6 and 36-month probabilities of not initiating DAA were 58% (95% CI: 55, 61) and 24% (21, 27), respectively. The 36-month risk of liver-related events was 1.1% (0.4, 2.0) for early initiation and 1.7% (0.7, 2.5) for delayed initiation; risk difference -0.5% (-1.2, 0.4). CONCLUSIONS: Almost one-quarter of people with HIV-HCV co-infection on ART had not initiated DAA 3 years after HIV virologic suppression. Because the 3-year risk of liver-related events was low, estimates of the impact of delayed DAA initiation were imprecise.
dc.language.isoENen_US
dc.title.enTime to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus
dc.title.alternativeAIDSen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/qad.0000000000004161en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed39970192en_US
bordeaux.journalAIDS. Official journal of the international AIDS Societyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionINRIA
bordeaux.teamSISTM_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-05029812
hal.version1
hal.date.transferred2025-04-10T16:02:02Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft.jtitle=AIDS.%20Official%20journal%20of%20the%20international%20AIDS%20Society&amp;rft.date=2025-02-19&amp;rft.eissn=1473-5571&amp;rft.issn=1473-5571&amp;rft.au=CHALOUNI,%20Mathieu&amp;VAN%20SANTEN,%20Daniela%20K&amp;BERENGUER,%20Juan&amp;JARRIN,%20Inmaculada&amp;MIRO,%20Jose%20M&amp;rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée